Innovating for a healthier future
We combine life-changing diagnostics and medicines to take on the toughest healthcare challenges, those that place the greatest strain on patients, families, communities and health systems.
Guided by the experiences of patients, we are determined to prevent, stop and cure diseases so people can live healthier, longer lives.
:quality(90)/)
“In 2025, Roche once again made significant progress: we continued on our growth path, launched important medical innovations and further strengthened our pipeline.”
Dr Thomas Schinecker
CEO Roche Group
“With excellent results and a promising product pipeline, our more than 100,000 employees have helped advance our vision of a healthier future.”
Dr Severin Schwan
Chairman
Discover how Roche made an impact in 2025
We built momentum in 2025 with our combined strength in pharmaceuticals and diagnostics, delivering progress for patients and pioneering new treatment options.
Performance figures 2025
+7%*
Group sales:
CHF 61.5 million
+9%
Pharmaceuticals sales:
CHF 47.7 million
+2%
Diagnostics sales:
CHF 13.8 million
+13%
Core operating profit:
CHF 21.8 million
–3%
R&D core investments:
CHF 12.2 million
+1%
Dividend proposal:
CHF 9.80
* Unless otherwise stated, all growth rates and comparisons to the previous year are at constant exchange rates (CER; average rates 2024) and all total figures quoted are reported in CHF.
Key highlights 2025
258 million lives
touched with our high-medical-value diagnostics solutions in 2025
More than 39 million patients
treated with our medicines
–34%
reduction in our scope 1 and 2 greenhouse gas emissions compared to 2024
100%
sustainable electricity goal achieved across our sites
For further information on how Roche defines and reports climate-related claims, please refer to our Climate-Related Claims Disclosure Statement.
United States
6
Lunsumio SC
Follicular lymphoma, third-line treatment
Tecentriq + lurbinectedin
Small cell lung cancer, first-line maintenance treatment
Gazyva/Gazyvaro
Lupus nephritis
TNKase
Stroke
Susvimo
Diabetic macular oedema
Susvimo
Diabetic retinopathy
Europe
5
Columvi + chemotherapy
Diffuse large B-cell lymphoma, second-line treatment
Itovebi + palbociclib + fulvestrant
Hormone receptor-positive, PIK3CAmutated, metastatic breast cancer, first-line treatment
Lunsumio SC
Follicular lymphoma, third-line treatment
Gazyva/Gazyvaro
Lupus nephritis
Xofluza
Influenza, paediatric (0–1 years)
China
4
Columvi + chemotherapy
Diffuse large B-cell lymphoma, second-line treatment
Itovebi + palbociclib + fulvestrant
Hormone receptor-positive, PIK3CAmutated, metastatic breast cancer, first-line treatment
Lunsumio
Follicular lymphoma, third-line treatment
Ocrevus
Relapsing multiple sclerosis and primary progressive multiple sclerosis
Japan – Chugai
6
Tecentriq
Alveolar soft part sarcoma
Tecentriq
Extranodal natural killer/T-cell lymphoma
Tecentriq
Unresectable thymic carcinoma
CellCept
Refractory nephrotic syndrome
Elevidys
Duchenne muscular dystrophy (ambulatory)
Vabysmo
Angioid streaks
Inside Science: exploring Alzheimer’s breakthroughs together
Alzheimer’s is a leading cause of death worldwide, creating a significant burden on healthcare systems, families and aging individuals.
:quality(90)/)